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Purpose: To assess the effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity when
administered for up to 3 years, evaluate the effect of delayed initiation of ranibizumab therapy on DR severity, and
identify baseline patient characteristics associated with the development of proliferative DR (PDR).
Design: Exploratory analyses of phase III, randomized, double-masked, sham-controlled multicenter clinical
trials.
Participants: Adults with diabetic macular edema (DME) (N ¼ 759), baseline best-corrected visual acuity
20/40 to 20/320 Snellen equivalent, and central foveal thickness 275 mm.
Methods: Patients were randomized to monthly 0.3 or 0.5 mg ranibizumab or sham injections. Sham par-
ticipants could switch to 0.5 mg ranibizumab during the third year (sham/0.5 mg crossover). Baseline risk factors
were evaluated to explore potential associations with development of PDR. Time to ﬁrst development of PDR was
analyzed by KaplaneMeier methods to calculate cumulative probabilities by group.
Main Outcome Measures: Study eye change on the Early Treatment Diabetic Retinopathy Study severity
scale and a composite clinical outcome evaluating progression to PDR based on photographic changes plus
clinically important events deﬁning PDR.
Results: At month 36, a greater proportion of ranibizumab-treated eyes had 2- or 3-step DR improvement
compared with sham/0.5 mg crossover. A 3-step improvement was achieved at 36 months by 3.3%, 15.0%,
and 13.2% of sham/0.5 mg, 0.3 mg, and 0.5 mg ranibizumab-treated eyes, respectively (P < 0.0001). Through 36
months, 39.1% of eyes in the sham/0.5 mg group developed PDR, as measured by composite outcome,
compared with 18.3% and 17.1% of eyes treated with 0.3 or 0.5 mg ranibizumab, respectively. The presence of
macular capillary nonperfusion at baseline seems to be associated with progression to PDR in ranibizumab-
treated eyes but did not meaningfully inﬂuence visual acuity improvement in eyes with DME after ranibizumab
therapy.
Conclusions: Ranibizumab, as administered to patients with DME for 12 to 36 months in these studies, can
both improve DR severity and prevent worsening. Prolonged delays in initiation of ranibizumab therapy may limit
this therapeutic effect. Although uncommon, the development of PDR still occurs in a small percentage of eyes
undergoing antievascular endothelial growth factor therapy and may be related to the presence of macular
nonperfusion. Ophthalmology 2015;122:367-374 ª 2015 by the American Academy of Ophthalmology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Supplemental material is available at www.aaojournal.org.Diabetic retinopathy (DR) is a leading cause of visual loss in
the United States, with a prevalence of more than 40% in
patients aged >40 years with diabetes.1 Two general DR
subtypes exist: nonproliferative DR (NPDR) and prolifera-
tive DR (PDR). Diabetic macular edema (DME) may be
present in eyes with either subtype and is frequently the
primary cause of vision loss due to DR. Another major
cause of vision loss in patients with DR is the development
of retinal neovascularization (e.g., PDR) and its accompa-
nying complications. The natural history of NPDR in many
patients is a slow, inexorable worsening, with characteristic 2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/). Published by Elsevier Inc.changes that occur in well-deﬁned and discrete steps. The
level of DR severity, as observable on retinal color fundus
photographs, is described by the standardized Early Treat-
ment Diabetic Retinopathy Study (ETDRS) DR severity
scale.2 The discrete changes that occur with disease
progression leading up to the development of frank
neovascularization provide an opportunity to evaluate the
effectiveness of new therapies that may arrest the progres-
sion of the disease or even reverse it.
In a prior report from our group,3 we described the effects
of monthly intravitreal antievascular endothelial growth367http://dx.doi.org/10.1016/j.ophtha.2014.08.048
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Ophthalmology Volume 122, Number 2, February 2015factor (VEGF) therapy with ranibizumab for 24 months on
DR severity using data from the RIDE and RISE phase III
clinical trials that evaluated the efﬁcacy and safety of rani-
bizumab for DME. In that exploratory analysis, we showed
that monthly ranibizumab for 24 months had profound and
beneﬁcial effects on DR severity: treatment with ranibizu-
mab prevented the worsening of DR (i.e., ETDRS severity
level progression) and led to DR improvement (i.e., ETDRS
severity level reduction). A composite measure evaluating
PDR development also was used to demonstrate the beneﬁt
of ranibizumab; this composite outcome included not only
the described fundus photographic changes, but also clinical
measures, such as the need for panretinal laser photocoag-
ulation or vitrectomy as treatment for complications of
PDR. We noted that sham-treated patients were 3-fold more
likely to develop PDR than patients treated with ranibizu-
mab over 24 months (33.8% vs. 11.2%e11.5%, respec-
tively).3 Retarding the progression of DR has been reported
in analyses from other studies of intravitreal agents (i.e.,
anti-VEGF therapies, steroids), as well as with systemic
therapies, such as candesartan and fenoﬁbrate.4e8
Compelling preclinical and clinical data suggest that the
retinal pathophysiology of DR is mediated in substantial
part by VEGF.9e12 Therefore, based on the biological
plausibility that VEGF plays an important role in the clinical
course of diabetic eye disease, further studies are needed to
evaluate anti-VEGF therapies for the modiﬁcation of DR
progression.
In the RIDE and RISE trials, the active-treatment arms
were assigned to monthly ranibizumab therapy for 36 months.
Patients randomized to sham for the ﬁrst 24 months were
eligible for crossover to 0.5 mg ranibizumab monthly
(sham/0.5 mg) starting at month 25. Thus, in this report we
compare the effect of a 2-year delay in the initiation of
treatment with ranibizumab on retinopathy severity level
between the ranibizumab treatment arms and the sham/
0.5 mg crossover arm at month 36. Although in RIDE and
RISE ranibizumab therapy signiﬁcantly reduced the rate of
progression to PDR at 24 months versus sham, a small
percentage of eyes treated with monthly intravitreal ranibi-
zumab nevertheless experienced a progression from non-
proliferative to proliferative disease. Thus, in the current
analysis we also sought to determine baseline risk factors
associated with the development of PDR. Previously, clin-
ical factors that have been associated with an increased
long-term risk of developing PDR included elevated he-
moglobin A1c (HbA1c), longer duration of diabetes, other
markers of diabetes severity and microvascular damage (i.e.,
proteinuria, neuropathy), and elevated blood pressure.13e19
Further exploration of potential risk factors for progression
to PDR despite treatment with anti-VEGF therapy is
important because identiﬁcation of eyes at risk may allow
for intensiﬁed therapy and/or closer monitoring of patients
when needed to reduce the likelihood of developing this
vision-threatening complication. In addition, identiﬁcation
of subgroups at higher risk of developing PDR even in the
setting of anti-VEGF therapy is important because these
patients may have unique genetic or other characteristics
that could help identify additional target pathways for future
therapeutics in retinal vascular disease.368Methods
Clinical Trial Design
RIDE and RISE were methodologically identical, randomized,
phase III, double-masked, sham injectionecontrolled clinical trials
of ranibizumab in patients with DME; the design, baseline patient
characteristics, and core efﬁcacy and safety outcomes of the trials
have been described elsewhere.3,20 Study protocols were approved
by institutional review boards and ethics committees, and partici-
pants provided written informed consent. RIDE and RISE
are registered on ClinicalTrials.gov with registration identiﬁers
NCT00473382 and NCT00473330, respectively.
Patients and Treatment
Individuals aged 18 years and older with decreased vision due
to DME (study eye best-corrected visual acuity [BCVA] of
20/40e20/320 approximate Snellen equivalent) and central foveal
thickness 275 mm on time-domain optical coherence tomography
(OCT) were eligible for enrollment. One eye per patient was
randomized to monthly sham injections or intravitreal injections
of 0.3 or 0.5 mg ranibizumab through month 24. From months
24 to 36, patients originally randomized to ranibizumab continued
with monthly therapy at their assigned dosage. Patients initially
randomized to sham were eligible to switch to 0.5 mg ranibizumab
monthly starting at month 25. In this report, this is referred to as the
“sham/0.5 mg” or “sham/0.5 mg crossover” group.
Grading Protocol and Clinical Assessment of
Diabetic Retinopathy Progression
Stereoscopic 7-ﬁeld color fundus photographs were obtained at
each patient’s screening visit and at months 3, 6, 12, 18, 24, 30,
and 36. Photographs were graded according to the ETDRS severity
scale for retinopathy level and were evaluated and deﬁned in the
same manner as previously described.3 To include the clinically
important DR progression events occurring between the periodic
photographic assessments, we measured DR progression using the
same composite outcome as previously described.3,21
Statistical Analyses
Baseline distributions of retinopathy severity were assessed and were
similar across the RIDE and RISE studies; thus, data were pooled for
these analyses. Unless otherwise speciﬁed, analyses of the outcomes
are based on the assessment of the study eye only. The ETDRS
retinopathy severity level was summarized over time. The number of
eyes worsening (i.e., ETDRS level progression) or improving (i.e.,
ETDRS level reduction) by 2 or 3 steps from baseline were
summarized at month 36. CochraneManteleHaenszel chi-square
tests stratiﬁed for baseline study eye visual acuity (55 vs. >55
ETDRS letters), baseline HbA1c level (8% vs. >8%), and prior
treatment for DME in the study eye (yes vs. no) were used to compare
the rates of DR worsening and improvement among patients treated
with ranibizumab versus sham/0.5 mg; Pearson chi-square tests were
used to compare results between the ranibizumab groups and the
sham/0.5 mg crossover group. Missing data were imputed using the
last observation carried forward method.
The cumulative probability of developing PDR at month 36 was
analyzed in each treatment group using KaplaneMeier methods.
The log-rank test was used to compare the risk of developing PDR
among the treatment groups. Univariate and multivariate Cox pro-
portional hazard models were used to evaluate baseline risk factors
for progression to PDR for the sham- and ranibizumab-treated pa-
tients. As with the assessment of DR improvement/worsening, this
Figure 1. Distribution of patients by change in severity of diabetic retinopathy (DR) on Early Treatment Diabetic Retinopathy Study (ETDRS) severity
scale from baseline to 36 months. Reported values are the percentage of patients (numbers above circles) with the stated level of severity (in parentheses on
the y-axis) at each visit; the size of the circle represents the percentage of patients in the DR severity category at each respective visit. Percentages in each
column total 100%. Black lines represent the median level of DR severity over time. BL ¼ baseline; NPDR ¼ nonproliferative diabetic retinopathy; PDR ¼
proliferative diabetic retinopathy.
Ip et al  Long-term Effects of Ranibizumab on DR Severityevaluation of progression to PDR was also stratiﬁed by baseline
study eye visual acuity letter score (55 vs. >55 ETDRS letters),
baseline HbA1c level (8% vs.>8%), and prior treatment for DME
in the study eye (yes vs. no). Baseline factors emerging as signiﬁcant
in the univariate model were then carried forward into the multi-
variate analysis. The model used 3 approaches for assessing DRFigure 2. Baseline and month 36 fundus photographs of a patient treated with ra
severity. CFT ¼ central foveal thickness.severity: continuous (per-step change), ETDRS severity level
47 versus 53, and ETDRS severity level 53 versus 60.
Mean change in BCVA from baseline over time was summa-
rized by baseline macular capillary nonperfusion status among
patients treated with ranibizumab. A t test was used to compare the
mean change in BCVA at month 24 between the patients with andnibizumab. Images indicate substantial regression in the level of retinopathy
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Figure 3. Percentage of patients with improvement and worsening of diabetic
retinopathy severity level measured by change from baseline in Early Treat-
ment Diabetic Retinopathy Study (ETDRS) letters. Data at 36 months are
shown for patients treated with sham/0.5 mg (n ¼ 239), 0.3 mg ranibizumab
(n ¼ 234), and 0.5 mg ranibizumab (n ¼ 234). *P < 0.001 versus control
group. **P < 0.05 versus control group. Vertical bars are unadjusted 95%
conﬁdence intervals. Study eye P values versus sham/0.5 mg crossover were
adjusted for baseline study eye visual acuity (55 vs. >55 letters), baseline
hemoglobin A1c (8% vs.>8%), and study eye prior to treatment for diabetic
macular edema (yes vs. no; CochraneManteleHaenszel chi-square test).
Ophthalmology Volume 122, Number 2, February 2015without macular nonperfusion. This analysis was limited to data
at 24 months to enable comparison of risk factors for progression
to PDR between the ranibizumab groups and sham (before
crossover).
Results
Diabetic Retinopathy Severity in Patients with
Delayed Treatment (Sham/0.5 mg Crossover)
As shown in Figure 1, the median baseline DR severity level in all
3 treatment groups was moderately severe NPDR (ETDRS level
47). The median DR category improved by 2 levels of ETDRS
severity in participants treated with 0.3 or 0.5 mg ranibizumab
monthly (from moderately severe to mild NPDR), whereas in the
sham/0.5 mg crossover group, the median DR severity remained
constant. As described below, sham-treated eyes crossing over to
0.5 mg ranibizumab beneﬁted from anti-VEGF therapy with
respect to DR severity level; however, the median DR severity
level remained constant through 36 months, perhaps because manyTable 1. Participants Progressing to Proliferative Diabetic Retin
Progression Category
Baseline to Year 2
Sham
(n ¼ 257)
Ranibi
0.3 mg
(n ¼ 250)
Progression from NPDR to PDRy 18 3
Received PRP laser 31/21 2/2
Reported vitreous hemorrhage 41/23 13/13
Progression from NPDR to PDR
identiﬁed by ophthalmoscopy
33/9 6/4
Underwent vitrectomy 16/3 0/0
Reported iris neovascularization 2/0 1/0
Reported retinal neovascularization 23/0 1/0
Total with progression to PDR 74 22
Data shown are total/additional numbers of patients (not counted in preceding
NPDR ¼ nonproliferative diabetic retinopathy; PDR ¼ proliferative diabetic r
*Patients randomized to sham therapy were eligible for crossover to monthly 0
yDocumented on fundus photographs.
370patients in the sham group had already developed PDR during the
ﬁrst 24 months and thus could no longer signiﬁcantly improve on
the DR severity scale.
Diabetic Retinopathy Severity in Patients Treated
with Ranibizumab from Study Entry
Consistent with observations after 24 months of therapy,3 longer-
term (36-month) treatment with ranibizumab was associated with
substantial improvement in DR severity level (Fig 2). Eyes treated
with ranibizumab were substantially more likely to have a 2- and
3-step improvement (regression) in DR severity level (Fig 3).
Approximately 39% of ranibizumab-treated eyes had 2-step
improvement in DR severity at 36 months compared with only
24% of those in the sham/0.5 mg crossover group (P ¼ 0.0003 for
each comparison of ranibizumab dose vs. sham). Diabetic reti-
nopathy severity improved by 3 ETDRS levels in 15% and 13%
of eyes treated with 0.3 and 0.5 mg ranibizumab, respectively. This
is a signiﬁcantly greater reduction in severity compared with the
3% of eyes achieving this level of improvement in the sham/0.5 mg
crossover group (P < 0.0001 for each comparison of ranibizumab
dosage vs. sham), and corresponds to a 4- to 5-fold greater like-
lihood of achieving 3-step improvement in DR severity with
monthly ranibizumab therapy for 3 years. Of note, this is compared
with eyes that received only 1 year of 0.5 mg ranibizumab after a
2-year delay in treatment, during which these patients had been
assigned to sham therapy.
Proliferative Diabetic Retinopathy
More patients in the sham/0.5 mg crossover group progressed to
PDR compared with those receiving 36 months of ranibizumab
(Table 1). From baseline to 24 months (720 days), a total of 74 of
257 eyes in the sham treatment group progressed to PDR compared
with only 22 of 250 and 26 of 252 eyes in the 0.3 and 0.5 mg
ranibizumab groups, respectively.3 At month 36 (1090 days), 87 of
257 eyes in the sham/0.5 mg crossover group progressed to PDR
compared with only 32 of 250 eyes and 38 of 252 eyes in the
respective ranibizumab groups. Vitreous hemorrhage was the most
frequent manifestation of proliferative disease in ranibizumab-
treated eyes. In the sham and sham/0.5 mg crossover groups, vit-
reous hemorrhage and need for panretinal laser were the most
common evidence of progression to PDR.opathy During the 36-Month Controlled Treatment Period
Baseline to Year 3
zumab
Sham/XO*
(n ¼ 257)
Ranibizumab
0.5 mg
(n ¼ 252)
0.3 mg
(n ¼ 250)
0.5 mg
(n ¼ 252)
4 29 7 9
3/2 34/18 4/4 7/5
12/11 45/26 18/16 18/13
11/8 40/12 9/5 16/9
3/0 16/2 0/0 4/1
1/0 3/0 2/0 1/0
6/1 26/0 1/0 7/1
26 87 32 38
rows).
etinopathy; PRP ¼ panretinal photocoagulation; XO ¼ crossover.
.5 mg ranibizumab at month 25.
Figure 4. KaplaneMeier analysis of time to ﬁrst proliferative diabetic
retinopathy (PDR) progression from baseline in the pooled RIDE and RISE
population. Cumulative probabilities were calculated using the
KaplaneMeier method. Progression was deﬁned by (1) progression from
nonproliferative diabetic retinopathy (DR) (severity level <60) at baseline
to PDR (DR severity level 60) DR at a later time point; (2) need for
panretinal photocoagulation; (3) vitreous hemorrhage (adverse event or slit
lamp) grade 0 at baseline and >0 at a later time point; (4) case identiﬁed by
ophthalmoscopy; (5) vitrectomy; (6) iris neovascularization adverse event;
and (7) retinal neovascularization adverse event. *P < 0.0001. Dashed ver-
tical line indicates the sham crossover to 0.5 mg ranibizumab at month 25.
Ip et al  Long-term Effects of Ranibizumab on DR SeverityAn important outcome of this analysis was that treatment with
ranibizumab signiﬁcantly reduced the rate of developing PDR
(Fig 4). By month 36 (1090 days), the cumulative probability of
DR progression using the composite analysis was 39.1% of eyes in
the sham/0.5 mg crossover group versus 18.3% and 17.1% of eyes
treated with 0.3 and 0.5 mg ranibizumab, respectively
(P < 0.0001). From as early as month 6 of the studies, separation
in the rate of PDR incidence was evident between the ranibizumab
and sham groups. The rates of developing PDR were linear in all 3
treatment arms in the ﬁrst 24 months, and were consistently lower
in eyes receiving ranibizumab therapy. Although treatment withTable 2. Factors Identiﬁed with Univariate Analyses as Predi
Ocular Features Comparator Group
Sham-treated patients*
Central subﬁeld thickness (mm) Each 15-mm increase
Total retinal volume (mm3) Each unit increase
Focal or diffuse edema Diffuse vs. focal
Subretinal ﬂuid presence on OCT Yes vs. no
Bilateral DME involvement Yes vs. no
BCVA Each unit increase
Capillary loss within grid Yes vs. no
IOP Each unit increase
DR severity Each step increase
DR severity 47 vs. 53 ETDR
DR severity 53 vs. 60 ETDR
Central foveal thickness (mm) Each 15-mm increase
Contrast sensitivity Each unit increase
Retinal thickening at center of macula <2 vs. 2 refere
Ranibizumab-treated patients*
Capillary loss within grid Yes vs. no
Focal or diffuse edema Diffuse vs. focal
*All ocular features refer to the study eye.
BCVA ¼ best-corrected visual acuity; CI ¼ conﬁdence interval; DME ¼ diabet
Diabetic Retinopathy Study; IOP ¼ intraocular pressure; OCT ¼ optical coheranibizumab signiﬁcantly reduced the risk of progression to PDR
compared with sham therapy during the ﬁrst 2 years, when patients
in the sham group crossed over to 0.5 mg ranibizumab during the
third year, their rate of PDR development was attenuated and
comparable to the rates of progression seen in the active-treatment
arms in the ﬁrst 24 months; 13 eyes in the sham/0.5 mg crossover
group progressed to PDR during year 3 compared with 10 and 12
eyes in the 0.3 and 0.5 mg ranibizumab groups, respectively.
Baseline Predictive Factors of Proliferative Diabetic
Retinopathy Progression
Approximately 9% to 10% of eyes receiving monthly ranibizumab
therapy still developed PDR at 24 months, and for this reason we
sought to determine whether there were any systemic or ocular
characteristics that might be predictive of progression to PDR,
especially in the setting of chronic intravitreal anti-VEGF therapy.
To facilitate comparison of predictive risk factors in sham- and
ranibizumab-treated eyes, 24-month data were used. This evalua-
tion followed a sequential stepwise analysis; baseline characteris-
tics emerging as signiﬁcant in univariate analyses were carried
forward into multivariate analysis.
Using this methodology, baseline factors identiﬁed as not being
predictive of progression to PDR for both the sham and ranibizu-
mab-treated groups included duration of diabetes (years), HbA1c
level, proteinuria, renal failure, hypertension, and smoking status.
Several baseline characteristics were identiﬁed through univariate
analysis to be predictive of progression to PDR (Table 2).
In sham-treated eyes, these included baseline DR severity
(ETDRS level 53), baseline DR severity (60), baseline DR
severity (each step increase), central foveal thickness (each unit
increase), central subﬁeld thickness (each unit increase), total
retinal volume (each unit increase), diffuse-type edema on ﬂuo-
rescein angiography, presence of subretinal ﬂuid on OCT, bilateral
DME involvement, BCVA (each unit decrease), presence of
macular capillary loss within the central grid on ﬂuorescein angi-
ography, contrast sensitivity (each unit decrease), retinal thickening
at the center of the macula (2 reference), and intraocular
pressure (decrease). In ranibizumab-treated eyes, only 2 factorsctive of Progression to Proliferative Diabetic Retinopathy
Hazard Ratio (95% CI) P Value
1.06 (1.03e1.09) 0.0001
1.22 (1.09e1.37) 0.0006
2.34 (1.39e3.95) 0.0015
1.85 (1.14e2.99) 0.0122
2.06 (1.12e3.77) 0.0195
0.97 (0.95e1.00) 0.0238
1.73 (1.06e2.82) 0.0276
0.92 (0.85e0.99) 0.0356
1.44 (1.22e1.69) <0.0001
S level 0.33 (0.20e0.54) <0.0001
S level 0.36 (0.22e0.59) <0.0001
1.03 (1.01e1.06) 0.0084
0.35 (0.15e0.81) 0.0138
nce 0.58 (0.36e0.91) 0.0185
2.50 (1.35e4.64) 0.0037
1.94 (1.02e3.71) 0.0444
ic macular edema; DR ¼ diabetic retinopathy; ETDRS ¼ Early Treatment
rence tomography.
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Table 3. Factors Identiﬁed with Multivariate Analyses as Predic-
tive of Progression to Proliferative Diabetic Retinopathy
Comparator
Groups
Hazard Ratio
(95% CI)
P
Value
Sham-treated patients*
DR severity (ETDRS level) 53 vs. 47 4.23 (2.24e7.98) <0.0001
Subretinal ﬂuid
presence on OCT
Yes vs. no 1.93 (1.02e3.63) 0.0422
Ranibizumab-treated patients*
Capillary loss within grid Yes vs. no 2.42 (1.30e4.49) 0.0052
CI ¼ conﬁdence interval; DR ¼ diabetic retinopathy; ETDRS ¼ Early
Treatment Diabetic Retinopathy Study; OCT ¼ optical coherence
tomography.
*All ocular features refer to the study eye. Figure 6. Mean change in best-corrected visual acuity (BCVA) from
baseline in ranibizumab-treated patients with or without baseline macular
capillary nonperfusion. ETDRS ¼ Early Treatment Diabetic Retinopathy
Study.
Ophthalmology Volume 122, Number 2, February 2015were identiﬁed with univariate analysis: diffuse-type edema on
ﬂuorescein angiography and presence of macular capillary loss
within the central grid on ﬂuorescein angiography.
By taking the baseline factors preliminarily identiﬁed with uni-
variate analysis forward into a multiple covariate regression model,
only 3 factors seemed to be prognostic of progression to PDR. At 24
months, subjects in the sham-treatment group who had more severe
DR (ETDRS category 53) at baseline were more likely to expe-
rience progression to PDR than those with baseline ETDRS severity
47 (hazard ratio [HR], 4.23; 95% conﬁdence interval [CI],
2.24e7.98; P < 0.0001). In addition, progression to PDR was more
likely in sham-treated patients who had subretinal ﬂuid present on
OCT at baseline (HR, 1.93; 95% CI, 1.02e3.63; P ¼ 0.0422).
Baseline macular capillary loss within the central grid on ﬂuo-
rescein angiography was the only prognostic factor for progression to
PDR identiﬁed by multiple covariate analysis in ranibizumab-treated
patients (Table 3 and Table 4 [available at www.aaojournal.org]). In
the pooled 0.3 and 0.5 mg ranibizumab group, 17.5% of eyes with
macular capillary loss had PDR at month 24 compared with 7.5% of
eyes without macular capillary loss (Fig 5). Thus, eyes with macular
capillary nonperfusion were signiﬁcantly more likely to have
developed PDR at 24 months (HR, 2.42; 95% CI, 1.30e4.49;
P ¼ 0.0052). However, ranibizumab treatment for DME was simi-
larly beneﬁcial both in patients with or without macular capillary
nonperfusion. The mean improvement in BCVA in eyes with baseline
macular nonperfusion was 14.5 ETDRS letters from a baseline mean
BCVAof 54.1 letters (Fig 6). By comparison, in eyes without macular
capillary loss, BCVA improved by a mean of 12.3 letters from a
baseline of 58.7 letters (P value for difference between groups ¼
0.1043). Therefore, although nonperfusion was a prognostic factor forFigure 5. Effect of baseline macular capillary nonperfusion on time to ﬁrst
progression to proliferative diabetic retinopathy in ranibizumab-treated patients.
372DR severity worsening in the context of anti-VEGF therapy, its
presence did not have a meaningful effect on the degree of improve-
ment in visual acuity associated with ranibizumab therapy.Discussion
This analysis of data, derived from 2 large randomized trials
of ranibizumab for the treatment of DME, provides strong,
long-term evidence that ranibizumab is effective for
improvement of DR severity and inhibition of disease pro-
gression. The risk of developing PDR was approximately
3-fold higher in eyes assigned to sham/0.5 mg crossover
compared with those randomized to monthly ranibizumab
therapy, whereas ranibizumab-treated eyes were more likely
to have a 2- and 3-step regression (i.e., improvement) in
DR severity level. It is worth noting that this level of effect
on DR severity was achieved with monthly intravitreal in-
jections, which may be a signiﬁcant treatment burden for
some patients. Changes in DR severity after cessation of
ranibizumab injections cannot be assessed by the data from
this study because of the study design. However, in the
RIDE/RISE extension study in which participants were fol-
lowed for an additional 2 years (5 years from randomization),
a cohort of participants were not re-treated because of sta-
bility of macular edema. The status of DR severity level in
that cohort will be the subject of a future report.
The observations presented underscore the importance of
early treatment for DME, as emphasized by the early sep-
aration of the KaplaneMeier PDR incidence curves. The
data demonstrate that eyes treated with ranibizumab after a
24-month sham period still experienced a reduction in the
rate of progression to PDR. However, by 24 months, 32% of
sham-treated patients had already progressed to PDR during
the 2-year delay before switching to ranibizumab, compared
with only 10% to 11% of patients who had received rani-
bizumab from the start of the trial. In short, delayed therapy
still seems beneﬁcial in preventing further disease progres-
sion, but treatment administered early in the course of DME
maximizes treatment beneﬁts.
Therefore, these data suggest that a delay in DME ther-
apy with ranibizumab foregoes an opportunity to reduce DR
Ip et al  Long-term Effects of Ranibizumab on DR Severityseverity and prevent disease progression. These results add
further weight to the conclusions of our prior report,3
namely that ranibizumab or a combination of ranibizumab
plus focal laser treatment should be considered in eyes in
which either therapy (ranibizumab or focal laser alone) may
be appropriate, in order to take full advantage of the addi-
tional beneﬁcial effect of ranibizumab therapy on reducing
DR severity.
In the pooled RIDE and RISE studies, systemic factors
such as baseline duration of diabetes, HbA1c, proteinuria,
renal failure, hypertension, and smoking status were not
signiﬁcantly associated with the development of PDR. While
other studies have demonstrated these factors to be associated
with DR development and worsening, they may not have
been prognostic in the RIDE/RISE studies, because in this
patient population with DME, a substantial disease burden
was already present at baseline (i.e., late-stage DR compli-
cations had already developed). We speculate that in these
patients, intraocular conditions such as the degree of macular
capillary nonperfusion may contribute more to DR wors-
ening than systemic factors, especially over a relatively short
(2-year) time period. Of note, in these data the only baseline
factor in ranibizumab-treated patients that was predictive of
progression to PDR was the presence of macular capillary
nonperfusion on ﬂuorescein angiography. Although macular
capillary nonperfusion was predictive of progression to PDR,
it was not predictive of gains in visual acuity achieved with
ranibizumab therapy. One might speculate that eyes with
baseline capillary nonperfusion would have both worse
vision and worse outcomes with treatment, but this was not
observed; similar gains in BCVA after ranibizumab therapy
were seen whether macular capillary nonperfusion was pre-
sent or absent. This may be related to the effects of VEGF
inhibition on retinal nonperfusion in the setting of diabetes,
as recently discussed by Campochiaro et al.22
In a small proportion of eyes (w10%), anti-VEGF
therapy was not effective for the prevention of progression
to PDR. In these eyes, disease progression may have
resulted from VEGF-independent pathways. The therapeutic
intraocular concentration achieved with monthly ranibizu-
mab is several orders of magnitude above the VEGF
receptor half maximal inhibitory concentration. The ranibi-
zumab half-maximal in vitro inhibitory concentration for
the VEGF receptor has been estimated at approximately
3 ng/ml,23 whereas the trough steady-state intravitreal con-
centration of ranibizumab achieved with monthly dosing
ranges from 12 000 to 20 000 ng/ml (0.3 and 0.5 mg doses,
respectively).24 Therefore, pathways other than that medi-
ated by VEGF likely contribute to or are the cause of disease
progression in these eyes, perhaps particularly so in the
group of patients identiﬁed as having macular capillary
nonperfusion. Combined with the hypoxia/ischemia result-
ing from degradation of retinal vessels, the ongoing biologic
insults associated with metabolic dysfunction (hyperglyce-
mia, hypertension, and dyslipidemia) can compromise vi-
sual function through several VEGF-independent signaling
cascades. For example, Gologorsky et al25 reviewed a
multitude of other pathways that may contribute to DR
pathophysiology, including growth factor modulation (e.g.,
insulin-like growth factors, angiopoietin), activation ofmatrix metalloproteinases, and a diversity of responses that
lie downstream of inﬂammatory cytokines that may be
elevated in patients with DR (e.g., transforming growth
factor-a and -b2 and interleukin-6 and -8).25 Therefore, the
observation in the RIDE/RISE studies that DR severity
continued to progress in a small proportion of eyes treated
with ranibizumab likely reﬂects the complex pathophysi-
ology of the disease. As new treatments targeting other
pathophysiologic mechanisms continue to be explored, we
might speculate that future therapies could use combination
regimens to arrest DR progression on multiple fronts.
In conclusion, these data demonstrate that modiﬁcation
of the natural course of DR can be achieved with intravitreal
ranibizumab. The data also highlight the importance of early
intervention in the DME patient population, in order to take
full advantage of the ancillary effect on DR severity level.
Lastly, this analysis identiﬁed macular nonperfusion as a
baseline risk factor for progression to PDR, and such eyes
may be considered for closer monitoring and/or ranibizumab
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